Trujillo, Peru Clinical Trials

A listing of Trujillo, Peru clinical trials actively recruiting patients volunteers.

Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 10 clinical trials
Phase III Study to Determine the Efficacy of Durvalumab in Combination With Chemotherapy in Completely Resected Stage II-III Non-small Cell Lung Cancer (NSCLC)

This is a Phase III, randomized, parallel-arm, placebo controlled, double blind, multicenter study assessing the efficacy and safety of durvalumab versus placebo following SoC chemotherapy in patients with completely resected stage II-III NSCLC who are MRD+ post surgery

cancer chemotherapy
durvalumab
lung carcinoma
Research Site
 (0.8 away) Contact site
  • 102 views
  • 25 Jul, 2021
  • +245 other locations
Durvalumab Treatment in Combination With Chemotherapy and Bevacizumab Followed by Maintenance Durvalumab Bevacizumab and Olaparib Treatment in Advanced Ovarian Cancer Patients

This is a Phase III randomised, double-blind, multi-centre study to evaluate the efficacy and safety of durvalumab in combination with standard of care platinum based chemotherapy and bevacizumab followed by maintenance durvalumab and bevacizumab or durvalumab, bevacizumab and olaparib in patients with newly diagnosed advanced ovarian cancer.

Research Site
 (4.8 away) Contact site
  • 84 views
  • 31 Jul, 2021
  • +292 other locations
Efficacy and Safety of Olaparib (MK-7339) in Participants With Previously Treated Homologous Recombination Repair Mutation (HRRm) or Homologous Recombination Deficiency (HRD) Positive Advanced Cancer (MK-7339-002 / LYNK-002)

This study will evaluate the efficacy and safety of olaparib (MK-7339) monotherapy in participants with multiple types of advanced cancer (unresectable and/or metastatic) that: 1) have progressed or been intolerant to standard of care therapy; and 2) are positive for homologous recombination repair mutation (HRRm) or homologous recombination deficiency (HRD).

Hospital de Alta Complejidad de La Libertad Virgen de La Puerta ( Site 3102)
 (0.9 away) Contact site
  • 175 views
  • 02 Aug, 2021
  • +146 other locations
A Study of Trastuzumab Deruxtecan (T-DXd) Versus Trastuzumab Emtansine (T-DM1) in High-risk HER2-positive Participants With Residual Invasive Breast Cancer Following Neoadjuvant Therapy (DESTINY-Breast05)

Patients with HER2-positive primary breast cancer (BC) who do not achieve complete response after appropriate neoadjuvant therapy are at higher risk of disease recurrence. More effective treatment options are needed for this patient population. This study will examine the efficacy and safety of trastuzumab deruxtecan (T-DXd) compared with trastuzumab emtansine …

Centro de Investigaci n Clinica Trujillo EIRL
 (0.9 away) Contact site
  • 0 views
  • 17 Jul, 2021
  • +425 other locations
A Study of Osimertinib With or Without Chemotherapy Versus Chemotherapy Alone as Neoadjuvant Therapy for Patients With EGFRm Positive Resectable Non-Small Cell Lung Cancer

This is a Phase III, randomised, controlled, 3-arm, multi-centre study of neoadjuvant osimertinib as monotherapy or in combination with chemotherapy, versus SoC chemotherapy alone, for the treatment of patients with resectable EGFRm Non-Small Cell Lung Cancer

carboplatin
cancer chemotherapy
lung carcinoma
pemetrexed
osimertinib
Research Site
 (4.8 away) Contact site
  • 0 views
  • 22 Jul, 2021
  • +138 other locations
Safety and Efficacy Study of Cefepime/VNRX-5133 in Patients With Complicated Urinary Tract Infections

This study will assess the safety and efficacy of cefepime/VNRX-5133 compared with meropenem in both eradication of bacteria and in symptomatic response in patients with cUTIs.

meropenem
acute pyelonephritis
pyelonephritis
cefepime
Site 160404
 (0.8 away) Contact site
  • 145 views
  • 28 Jun, 2021
  • +102 other locations
A Study of Osimertinib With or Without Chemotherapy as 1st Line Treatment in Patients With Mutated Epidermal Growth Factor Receptor Non-Small Cell Lung Cancer (FLAURA2)

The reason for the study is to find out if an experimental combination of an oral medication called osimertinib (TAGRISSO) when used in combination with chemotherapy is more effective than giving osimertinib alone for the treatment of locally advanced or metastatic non-small cell lung cancer. Some lung cancers are due …

epidermal growth factor receptor
carboplatin
osimertinib
non-squamous non-small cell lung cancer
recurrent non-small cell lung cancer
Research Site
 (4.8 away) Contact site
  • 811 views
  • 21 Jul, 2021
  • +171 other locations
Study Assessing the Efficacy and Safety of Alpelisib + Nab-paclitaxel in Subjects With Advanced TNBC Who Carry Either a PIK3CA Mutation or Have PTEN Loss

The purpose of this study is to determine whether treatment with alpelisib in combination with nab-paclitaxel is safe and effective in subjects with advanced triple negative breast cancer (aTNBC) who carry either a PIK3CA mutation (Study Part A) or have PTEN loss (Study Part B1) or PTEN loss without PIK3CA …

measurable disease
PIK3CA
cancer
breast cancer
mammogram
Novartis Investigative Site
 (296.9 away) Contact site
  • 5 views
  • 14 Jul, 2021
  • +151 other locations
Study of Chemoradiotherapy With or Without Pembrolizumab (MK-3475) For The Treatment of Locally Advanced Cervical Cancer (MK-3475-A18/KEYNOTE-A18/ENGOT-cx11/GOG-3047)

The purpose of this study is to evaluate the efficacy and safety of pembrolizumab plus concurrent chemoradiotherapy compared to placebo plus concurrent chemoradiotherapy in participants with locally advanced cervical cancer. The primary hypotheses are that pembrolizumab plus concurrent chemoradiotherapy is superior to placebo plus concurrent chemoradiotherapy with respect to progression-free …

squamous cell carcinoma
adenosquamous carcinoma
brachytherapy
carcinoma
cancer
Hospital de Alta Complejidad de La Libertad Virgen de La Puerta ( Site 0287)
 (4.8 away) Contact site
  • 87 views
  • 16 Jul, 2021
  • +160 other locations
A Study of Neoadjuvant/Adjuvant Durvalumab for the Treatment of Patients With Resectable Non-small Cell Lung Cancer

This is a Phase III, randomized, double-blind, placebo-controlled, multi-center international study assessing the activity of durvalumab and chemotherapy administered prior to surgery compared with placebo and chemotherapy administered prior to surgery in terms of pathological complete response.

carboplatin
durvalumab
pemetrexed
carboplatin/paclitaxel
EGFR
Research Site
 (4.8 away) Contact site
  • 251 views
  • 31 Jul, 2021
  • +318 other locations